Sign Up for Generic Drugs Class Action Lawsuit
Generic Drugs class action lawsuit is currently open:
Those who meet eligibility criteria should apply before the deadline November 5, 2026. Generic drug class action: Sandoz, Sun and Taro agreed to pay $475 million. Paid out of pocket for one of 197 generics from 2009 to 2019? You may qualify.
Generic Drugs Class Action Lawsuit
Generic drugs are meant to be the cheap option, so a refill that suddenly cost far more stood out. This generic drug class action says that was no accident. According to the complaint, Teva raised its list prices for dextroamphetamine tablets by more than 800% at the end of July 2012, and in March 2013 Sandoz set list prices for methylphenidate tablets, the generic form of Ritalin, about five times higher than before. The complaint says rivals matched both increases within weeks instead of undercutting them.
The generic drug price-fixing lawsuit claims drug makers followed a rule they called “fair share”: each company kept an agreed slice of a drug’s customers and did not chase the others’ business with lower prices. They had to “play nice in the sandbox,” the complaint says. It also says Justice Department criminal cases led to fines of $195 million for Sandoz and $205.6 million for Taro.
The case is In re Generic Pharmaceuticals Pricing Antitrust Litigation, MDL No. 2724, before Judge Cynthia M. Rufe in the U.S. District Court for the Eastern District of Pennsylvania. It was brought by end-payers, meaning whoever pays for a drug last: patients, and the insurers and health plans known as third-party payers. The named plaintiffs, who sue on behalf of everyone else, include union health funds and three consumers. Class counsel, the court-appointed lawyer for the class, is Roberta D. Liebenberg of Fine, Kaplan and Black. Sandoz, Sun and Taro deny wrongdoing in this lawsuit, and the case continues against other drug makers.
Generic Drugs Class Action Settlement - $475,000,000
The generic drug settlement is two deals covered by one claim form. The Sandoz settlement, with Sandoz and Fougera Pharmaceuticals, was set at $275,000,000 and won final approval on September 26, 2025. The Sun Pharma Taro settlement added $200,000,000 and was approved on January 23, 2026, after a hearing on January 15, 2026. That is $475,000,000 on paper. The Sandoz deal let up to $45,000,000 go back to Sandoz if large payers left the class, and class counsel later put that fund at about $239,200,000. Nothing went back to Sun and Taro.
Not all of that money reaches claimants. From the Sandoz fund the court awarded the lawyers one third of what is left after costs, plus $25,700,911 in expenses and $410,000 in service awards for the health funds and consumers who represented the class. From the Sun and Taro fund the lawyers asked for one third, $304,955 in expenses, $3,000,000 held back for the continuing case, and $30,000 for each health plan and $5,000 for each consumer. The court found those amounts appropriate. Notice and administration can take up to $750,000 from each fund.
Money from uncashed payments can be shared again among claimants who cashed theirs. A remainder too small to divide can be held for later or, if the court agrees, go to legal fees or to a cy pres payment, a legal term for money given to a cause that benefits the class. The time to opt out or object has passed. The deadline to file a claim is November 5, 2026. The claims administrator is A.B. Data, at 1-877-316-0171.
Deadline for filing a claim: November 5, 2026
Generic Drug Makers Class Action Payout: $10 per $1,000 spent (estimate)
Nobody can state the generic drug settlement payout per person yet, so here is an estimate and how we got it. Start with about $239,200,000 from Sandoz. Take out $750,000 for notice and administration, $25,700,911 in expenses and $410,000 in service awards, then one third for the lawyers, and about $141,600,000 is left. Do the same sums for the $200,000,000 from Sun and Taro and about $130,400,000 is left. Together that is roughly $272,000,000 before interest.
That money is paid pro rata, which means each claimant’s share matches what they spent on the named drugs. Consumers share one pool with insurers and health plans, so the rate depends on the total everyone claims, and the court papers give no claim totals yet. Our estimate is about 1 cent back for each dollar you paid, or about $10 on $1,000 of out-of-pocket spending. It assumes claims add up to about $27 billion. For scale, the complaint puts U.S. sales of all generic drugs at $74.5 billion in 2015 alone. If half as much is claimed the rate doubles, and if twice as much is claimed it halves.
So expect a modest amount unless you spent a lot. Attorneys general from 42 states told the court consumers were unlikely to see meaningful money; the judge answered that each payment is proportional to the loss. The administrator may also recommend a minimum payment. Eligible payments are sent after claims are reviewed and the court approves the distribution, and no date has been set. The claim form offers direct deposit, Zelle, PayPal, Venmo or a paper check.
Generic Drug Makers Class Action Eligibility
Generic drug settlement eligibility comes down to the drug, the dates and the place. You are covered if you paid some or all of the price of at least one of the 197 named generic drugs, for your own use, between May 1, 2009, and December 31, 2019, in any state except Indiana and Ohio, or in the District of Columbia, Puerto Rico or the U.S. Virgin Islands. A copay counts. The list includes generic Adderall, doxycycline, pravastatin, levothyroxine, gabapentin, fluoxetine and prednisone, each in specific forms and strengths.
Some purchases that look similar do not count. Anything Medicaid covered is out, although your other purchases still count. Only the forms and strengths on the list qualify, so metformin is covered only as certain extended-release tablets or in combination pills. List only what you paid, not what your insurer paid. Drugs bought to resell or bought straight from a manufacturer are out, and so are employees of the drug makers being sued.
The claim form asks for each drug’s list number and name, the total you paid for it, and at least one document per drug showing a purchase in those years: a receipt, a statement, or an itemized record your pharmacy prints on request. Getting that years later takes effort: the states told the court one class representative needed several pharmacy trips. You sign under penalty of perjury. Claims can be audited and cut or rejected, and false information can bring sanctions, including criminal prosecution. Claim the amount you are confident in: a smaller, accurate claim gets paid.
Generic Drug Makers Class Action Claim Form
1
2
3
FAQ
The lawsuit claims generic drug makers agreed to share out customers instead of competing, and raised prices on 197 drugs between 2009 and 2019. Sandoz, Sun and Taro deny wrongdoing in the lawsuit but agreed to pay $475,000,000 to settle.
The list has 197 drugs in specific forms and strengths. It includes generic Adderall, amoxicillin/clavulanate chewable tablets, doxycycline, pravastatin, levothyroxine, gabapentin, fluoxetine, prednisone and warfarin. The claim form asks for each drug by its list number.
A receipt, an invoice or an account statement that names the drug, or an itemized record of your purchases that your pharmacy prints when you ask. You need at least one dated between May 1, 2009, and December 31, 2019, for every drug you claim.
No. One document showing one purchase of a drug supports your claim for everything you paid for that drug over the period. The administrator can still ask for more records, and totals that look too high against average purchases can be cut.
Purchases made in Indiana or Ohio are not covered, and neither are purchases Medicaid covered. If Medicaid covered only some of your purchases, the others still count. Drugs bought to resell and employees of the drug makers being sued are also out.
Yes. The class includes anyone who paid some or all of the price, so a copay, coinsurance or deductible payment counts. List only the dollars you paid yourself. Your insurer or health plan can file its own claim for its part of the same purchase.
Our estimate is about 1 cent for each dollar you paid, or about $10 per $1,000 spent. Roughly $272,000,000 is left after fees and costs, and consumers share it with insurers in proportion to spending. The real rate depends on how much is claimed.
Filing is included in a Chimo membership, and Chimo takes no percentage of a class action payout. For that we prepare the claim form, have you sign it, and mail it to the claims administrator together with the pharmacy records you send us.
Claims are due by November 5, 2026. Eligible payments are sent after the administrator reviews the claims and the court approves the distribution. No payment date has been set, and the case is still going on against other drug makers.
You can file on your own, without a third party and at no cost. The court-appointed administrator, A.B. Data (1-877-316-0171), and the class’s lawyers help with claims at no cost. Chimo is optional: filing is included in a paid Chimo membership, and we take no percentage of a payout.
Sources
These are the court's own records for this case. They are hosted here unchanged, so you can check anything on this page against the documents themselves.
- Consumer Claim Form (Sandoz and Sun/Taro Settlements) (PDF) Claim form · U.S. District Court, Eastern District of Pennsylvania · Case 2:16-md-02724
- Long Form Notice: Sandoz Settlement (PDF) Class notice · U.S. District Court, Eastern District of Pennsylvania · Case 2:16-md-02724
- Long Form Notice: Sun/Taro Settlement (PDF) Class notice · U.S. District Court, Eastern District of Pennsylvania · Case 2:16-md-02724
- Settlement Agreement: Sandoz (PDF) Settlement agreement · U.S. District Court, Eastern District of Pennsylvania · Case 2:16-md-02724
- Settlement Agreement: Sun/Taro (PDF) Settlement agreement · U.S. District Court, Eastern District of Pennsylvania · Case 2:16-md-02724
- Order Granting Final Approval of the Sandoz Settlement (PDF) Court order · Filed September 26, 2025 · U.S. District Court, Eastern District of Pennsylvania · Case 2:16-md-02724
- Final Order and Judgment: Sun/Taro Settlement (PDF) Court order · Filed January 23, 2026 · U.S. District Court, Eastern District of Pennsylvania · Case 2:16-md-02724
- Order Approving Notices, Claim Forms and Claims Administrator (PDF) Court order · Filed June 10, 2026 · U.S. District Court, Eastern District of Pennsylvania · Case 2:16-md-02724
- End-Payer Second Multi-Drug Complaint (Second Amended, Public) (PDF) Complaint · Filed December 15, 2020 · U.S. District Court, Eastern District of Pennsylvania · Case 2:16-md-02724
- List of Named Generic Drugs (PDF) Court record · U.S. District Court, Eastern District of Pennsylvania · Case 2:16-md-02724